Brain Research Center Zwolle B.V.
- Address
- lock Available on a paid plan
Neurology and Alzheimer’s Disease Research
At Brain Research Center Zwolle B.V., the strongest focus is on nervous system diseases, especially Alzheimer’s disease and related forms of cognitive decline. The trials are designed to test new treatment options, assess symptom improvement, and better understand how therapies may affect memory and daily functioning in people with early and mild to moderate disease.
- Early and mild to moderate Alzheimer’s disease
- Cognitive impairment and decline in thinking skills
- Testing new therapies to slow disease progression and improve function
Several studies also look at biomarkers and brain changes, helping researchers evaluate whether treatments are affecting the underlying disease process.
Parkinson’s Disease and Movement Disorders
The site is also active in neurology research for Parkinson’s disease, including early-stage disease. These trials aim to evaluate whether investigational treatments can slow progression, preserve motor function, and support long-term disease control.
- Early-stage Parkinson’s disease
- Measuring treatment effectiveness in slowing progression
- Exploring new options for disease modification
This work reflects a broader effort in nervous system diseases to find therapies that may change the course of chronic neurodegenerative illness.
Cardiovascular and Metabolic Disease Studies
Research at this laboratory and testing facility also includes cardiovascular diseases and nutritional and metabolic diseases. Current trials focus on reducing the risk of heart failure and cardiovascular death, while also studying conditions linked to type 2 diabetes, hypertension, and established cardiovascular disease.
- Heart failure prevention and risk reduction
- Type 2 diabetes with cardiovascular complications
- Evaluating new combinations to improve cardiovascular outcomes
These studies aim to improve treatment effectiveness for people with overlapping metabolic and heart-related conditions.
Brain Health, Biomarkers, and Related Disorders
The Zwolle site contributes to research on how brain diseases can be tracked and treated more precisely, including studies in mental disorders and broader nervous system diseases. A number of trials examine biomarkers, imaging findings, and clinical progression to support earlier diagnosis and more targeted care.
- Investigating biomarkers linked to Alzheimer’s disease progression
- Using brain imaging to monitor treatment effects
- Supporting earlier and more accurate disease assessment
This research helps connect clinical symptoms with biological changes, offering a clearer picture of how different therapies may work in practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Brain Research Center Zwolle B.V.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer's Disease | Denali Therapeutics Inc. | Phase I | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetapir (18F) | 3 | Unknown | 2020-09-30 | 2025-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.